Budesonide and the risk of pneumonia: a meta-analysis of individual patient data

Don D. Sin, Donald Tashkin, Xuekui Zhang, Finn Radner, Ulf Sjöbring, Anders Thorén, Peter MA Calverley, Stephen I. Rennard

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

Background: Concern is continuing about increased risk of pneumonia in patients with chronic obstructive pulmonary disease (COPD) who use inhaled corticosteroids. We aimed to establish the effects of inhaled budesonide on the risk of pneumonia in such patients. Methods: We pooled patient data from seven large clinical trials of inhaled budesonide (320-1280 μg/day), with or without formoterol, versus control regimen (placebo or formoterol alone) in patients with stable COPD and at least 6 months of follow-up. The primary analysis compared treatment groups for the risk of pneumonia as an adverse event or serious adverse event during the trial or within 15 days of the trial end. Cox proportional hazards regression was used to analyse the data on an intention-to-treat basis. Data were adjusted for patients' age, sex, smoking status, body-mass index, and postbronchodilator percent of predicted forced expiratory volume in 1 s (FEV1). Findings: We analysed data from 7042 patients, of whom 3801 were on inhaled budesonide and 3241 were on control treatment, with 5212 patient-years of exposure to treatment. We recorded no significant difference between treatment groups for the occurrence of pneumonia as an adverse event (3% [n=122 patients] vs 3% [n=103]; adjusted hazard ratio 1·05, 95% CI 0·81-1·37) or a serious adverse event (1% [n=53] vs 2% [n=50]; 0·92, 0·62-1·35), or for time to pneumonia as an adverse event (log-rank test 0·94) or a serious adverse event (0·61). Increasing age and decreasing percent of predicted FEV1 were the only two variables that were significantly associated with occurrence of pneumonia as an adverse event or a serious adverse event. Interpretation: Budesonide treatment for 12 months does not increase the risk of pneumonia in patients with COPD during that time and therefore is safe for clinical use in such patients. Funding: Michael Smith Foundation for Health Research.

Original languageEnglish (US)
Pages (from-to)712-719
Number of pages8
JournalThe Lancet
Volume374
Issue number9691
DOIs
StatePublished - Sep 4 2009

Fingerprint

Budesonide
Meta-Analysis
Pneumonia
Chronic Obstructive Pulmonary Disease
Forced Expiratory Volume
Therapeutics
Adrenal Cortex Hormones
Body Mass Index
Smoking
Placebos
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sin, D. D., Tashkin, D., Zhang, X., Radner, F., Sjöbring, U., Thorén, A., ... Rennard, S. I. (2009). Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. The Lancet, 374(9691), 712-719. https://doi.org/10.1016/S0140-6736(09)61250-2

Budesonide and the risk of pneumonia : a meta-analysis of individual patient data. / Sin, Don D.; Tashkin, Donald; Zhang, Xuekui; Radner, Finn; Sjöbring, Ulf; Thorén, Anders; Calverley, Peter MA; Rennard, Stephen I.

In: The Lancet, Vol. 374, No. 9691, 04.09.2009, p. 712-719.

Research output: Contribution to journalArticle

Sin, DD, Tashkin, D, Zhang, X, Radner, F, Sjöbring, U, Thorén, A, Calverley, PMA & Rennard, SI 2009, 'Budesonide and the risk of pneumonia: a meta-analysis of individual patient data', The Lancet, vol. 374, no. 9691, pp. 712-719. https://doi.org/10.1016/S0140-6736(09)61250-2
Sin DD, Tashkin D, Zhang X, Radner F, Sjöbring U, Thorén A et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. The Lancet. 2009 Sep 4;374(9691):712-719. https://doi.org/10.1016/S0140-6736(09)61250-2
Sin, Don D. ; Tashkin, Donald ; Zhang, Xuekui ; Radner, Finn ; Sjöbring, Ulf ; Thorén, Anders ; Calverley, Peter MA ; Rennard, Stephen I. / Budesonide and the risk of pneumonia : a meta-analysis of individual patient data. In: The Lancet. 2009 ; Vol. 374, No. 9691. pp. 712-719.
@article{040a7461ce084e229979c3e8697035f0,
title = "Budesonide and the risk of pneumonia: a meta-analysis of individual patient data",
abstract = "Background: Concern is continuing about increased risk of pneumonia in patients with chronic obstructive pulmonary disease (COPD) who use inhaled corticosteroids. We aimed to establish the effects of inhaled budesonide on the risk of pneumonia in such patients. Methods: We pooled patient data from seven large clinical trials of inhaled budesonide (320-1280 μg/day), with or without formoterol, versus control regimen (placebo or formoterol alone) in patients with stable COPD and at least 6 months of follow-up. The primary analysis compared treatment groups for the risk of pneumonia as an adverse event or serious adverse event during the trial or within 15 days of the trial end. Cox proportional hazards regression was used to analyse the data on an intention-to-treat basis. Data were adjusted for patients' age, sex, smoking status, body-mass index, and postbronchodilator percent of predicted forced expiratory volume in 1 s (FEV1). Findings: We analysed data from 7042 patients, of whom 3801 were on inhaled budesonide and 3241 were on control treatment, with 5212 patient-years of exposure to treatment. We recorded no significant difference between treatment groups for the occurrence of pneumonia as an adverse event (3{\%} [n=122 patients] vs 3{\%} [n=103]; adjusted hazard ratio 1·05, 95{\%} CI 0·81-1·37) or a serious adverse event (1{\%} [n=53] vs 2{\%} [n=50]; 0·92, 0·62-1·35), or for time to pneumonia as an adverse event (log-rank test 0·94) or a serious adverse event (0·61). Increasing age and decreasing percent of predicted FEV1 were the only two variables that were significantly associated with occurrence of pneumonia as an adverse event or a serious adverse event. Interpretation: Budesonide treatment for 12 months does not increase the risk of pneumonia in patients with COPD during that time and therefore is safe for clinical use in such patients. Funding: Michael Smith Foundation for Health Research.",
author = "Sin, {Don D.} and Donald Tashkin and Xuekui Zhang and Finn Radner and Ulf Sj{\"o}bring and Anders Thor{\'e}n and Calverley, {Peter MA} and Rennard, {Stephen I.}",
year = "2009",
month = "9",
day = "4",
doi = "10.1016/S0140-6736(09)61250-2",
language = "English (US)",
volume = "374",
pages = "712--719",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9691",

}

TY - JOUR

T1 - Budesonide and the risk of pneumonia

T2 - a meta-analysis of individual patient data

AU - Sin, Don D.

AU - Tashkin, Donald

AU - Zhang, Xuekui

AU - Radner, Finn

AU - Sjöbring, Ulf

AU - Thorén, Anders

AU - Calverley, Peter MA

AU - Rennard, Stephen I.

PY - 2009/9/4

Y1 - 2009/9/4

N2 - Background: Concern is continuing about increased risk of pneumonia in patients with chronic obstructive pulmonary disease (COPD) who use inhaled corticosteroids. We aimed to establish the effects of inhaled budesonide on the risk of pneumonia in such patients. Methods: We pooled patient data from seven large clinical trials of inhaled budesonide (320-1280 μg/day), with or without formoterol, versus control regimen (placebo or formoterol alone) in patients with stable COPD and at least 6 months of follow-up. The primary analysis compared treatment groups for the risk of pneumonia as an adverse event or serious adverse event during the trial or within 15 days of the trial end. Cox proportional hazards regression was used to analyse the data on an intention-to-treat basis. Data were adjusted for patients' age, sex, smoking status, body-mass index, and postbronchodilator percent of predicted forced expiratory volume in 1 s (FEV1). Findings: We analysed data from 7042 patients, of whom 3801 were on inhaled budesonide and 3241 were on control treatment, with 5212 patient-years of exposure to treatment. We recorded no significant difference between treatment groups for the occurrence of pneumonia as an adverse event (3% [n=122 patients] vs 3% [n=103]; adjusted hazard ratio 1·05, 95% CI 0·81-1·37) or a serious adverse event (1% [n=53] vs 2% [n=50]; 0·92, 0·62-1·35), or for time to pneumonia as an adverse event (log-rank test 0·94) or a serious adverse event (0·61). Increasing age and decreasing percent of predicted FEV1 were the only two variables that were significantly associated with occurrence of pneumonia as an adverse event or a serious adverse event. Interpretation: Budesonide treatment for 12 months does not increase the risk of pneumonia in patients with COPD during that time and therefore is safe for clinical use in such patients. Funding: Michael Smith Foundation for Health Research.

AB - Background: Concern is continuing about increased risk of pneumonia in patients with chronic obstructive pulmonary disease (COPD) who use inhaled corticosteroids. We aimed to establish the effects of inhaled budesonide on the risk of pneumonia in such patients. Methods: We pooled patient data from seven large clinical trials of inhaled budesonide (320-1280 μg/day), with or without formoterol, versus control regimen (placebo or formoterol alone) in patients with stable COPD and at least 6 months of follow-up. The primary analysis compared treatment groups for the risk of pneumonia as an adverse event or serious adverse event during the trial or within 15 days of the trial end. Cox proportional hazards regression was used to analyse the data on an intention-to-treat basis. Data were adjusted for patients' age, sex, smoking status, body-mass index, and postbronchodilator percent of predicted forced expiratory volume in 1 s (FEV1). Findings: We analysed data from 7042 patients, of whom 3801 were on inhaled budesonide and 3241 were on control treatment, with 5212 patient-years of exposure to treatment. We recorded no significant difference between treatment groups for the occurrence of pneumonia as an adverse event (3% [n=122 patients] vs 3% [n=103]; adjusted hazard ratio 1·05, 95% CI 0·81-1·37) or a serious adverse event (1% [n=53] vs 2% [n=50]; 0·92, 0·62-1·35), or for time to pneumonia as an adverse event (log-rank test 0·94) or a serious adverse event (0·61). Increasing age and decreasing percent of predicted FEV1 were the only two variables that were significantly associated with occurrence of pneumonia as an adverse event or a serious adverse event. Interpretation: Budesonide treatment for 12 months does not increase the risk of pneumonia in patients with COPD during that time and therefore is safe for clinical use in such patients. Funding: Michael Smith Foundation for Health Research.

UR - http://www.scopus.com/inward/record.url?scp=69149110944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69149110944&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(09)61250-2

DO - 10.1016/S0140-6736(09)61250-2

M3 - Article

C2 - 19716963

AN - SCOPUS:69149110944

VL - 374

SP - 712

EP - 719

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9691

ER -